Drug-Device Combos Divide Orange Book Feedback
Major drugmakers, attorneys general and pharma trade organizations have given the U.S. Food and Drug Administration conflicting arguments on whether patents for drug-device combinations and established risk evaluation and mitigation strategies...To view the full article, register now.
Already a subscriber? Click here to view full article